Skip to Content

Carboplatin use while Breastfeeding

Drugs containing Carboplatin: Paraplatin, Carboplatin Novaplus

Carboplatin Levels and Effects while Breastfeeding

Summary of Use during Lactation

Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy, especially alkylating agents such as carboplatin.[1] It might be possible to breastfeed safely during intermittent therapy with an appropriate period of breastfeeding abstinence, but the duration of abstinence is not clear. In one case, carboplatin was still detectable in milk 13 days after a dose of 2.9 mg/kg. Chemotherapy may adversely affect the normal microbiome and chemical makeup of breastmilk.[2]

Drug Levels

Maternal Levels. A woman with a history of treatment for thyroid cancer and recurrence during pregnancy was treated postpartum with carboplatin and paclitaxel. Her intravenous carboplatin dose was 233 mg (2.9 mg/kg; AUC 1.5) weekly for 6 weeks. Whole milk samples were obtained before her 6th dose and at 4, 28, 172, and 316 hours after the dose. The highest milk carboplatin level was 0.9 mg/L in the 4-hour sample and carboplatin was still measurable (0.16 mg/L) in the 317 hour sample. Metabolites were not measured. The average milk carboplatin level over the 317 hour collection period was 0.4 mg/L, resulting in an estimated infant dose of 2% of the maternal dose.[3]

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1. Pistilli B, Bellettini G, Giovannetti E et al. Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: How should we counsel cancer patients about breastfeeding? Cancer Treat Rev. 2013;39:207-11. PMID: 23199900

2. Urbaniak C, McMillan A, Angelini M, Gloor GB et al. Effect of chemotherapy on the microbiota and metabolome of human milk, a case report. Microbiome. 2014;2 :24. PMID: 25061513

3. Griffin SJ, Milla M, Baker TE, Liu T, Wang H, Hale TW. Transfer of carboplatin and paclitaxel into breast milk. J Hum Lact. 2012;28:457-9. PMID: 23087196

Carboplatin Identification

Substance Name

Carboplatin

CAS Registry Number

41575-94-4

Drug Class

Antineoplastic Agents

Administrative Information

LactMed Record Number

1014

Last Revision Date

20141003

Disclaimer

Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Disclaimer: This information is not intended as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. Use of this website signifies your agreement to the Terms of Use and Online Privacy Policy.

Hide